[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. [2] Cohen PA,Jhingran A,Oaknin A,et al. Cervical cancer[J]. Lancet, 2019, 393(10167):169-182. [3] Xie F, Xie G, Sun Q. Long noncoding RNA DLX6-AS1 promotes the progression in cervical cancer by targeting miR-16-5p/ARPP19 Axis[J]. Cancer Biother Radiopharm, 2020, 35(2):129-136. [4] Zhang WY, Liu YJ, He Y, et al. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer[J]. J Cell Physiol, 2019, 234(4):4302-4313. [5] 李子博, 周江, 周琳, 等.长链非编码RNA CRNDE检测在乳腺癌诊断中的意义[J].实用预防医学,2018,25(3):276-279. [6] Ren Z, Liu X, Si Y, et al. Long non-coding RNA DDX11-AS1 facilitates gastric cancer progression by regulating miR-873-5p/SPC18 axis[J]. Artif Cells Nanomed Biotechnol, 2020, 48(1):572-583 [7] Tian JB, Cao L, Dong GL. Long noncoding RNA DDX11-AS1 induced by YY1 accelerates colorectal cancer progression through targeting miR-873/CLDN7 axis[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13):5714-5729. [8] Yu Y, Zhao JD, Yang H. MiR-299-3p inhibits proliferation and invasion of cervical cancer cell via targeting TCF4[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13):5621-5627. [9] Li Y, Zhuang W, Huang M, et al. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2019, 514(4):1051-1057. [10] Feng X, Yang S, Zhou S, et al. Long non-coding RNA DDX11-AS1 promotes non-small cell lung cancer development via regulating PI3K/AKT signaling[J]. Clin Exp Pharmacol Physiol, 2020,47(9):1622-1631. [11] Zhang S, Jiang H, Xu Z, et al. The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition[J]. Am J Cancer Res, 2019, 9(10):2233-2248. [12] Li D, Chai L, Yu X, et al. The HOTAIRM1/miR-107/TDG axis regulates papillary thyroid cancer cell proliferation and invasion[J]. Cell Death Dis, 2020, 11(4):227-237. [13] Song W, Qian Y, Zhang MH, et al. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(6):3049-3061. [14] Duan H, Li X, Chen Y, et al. LncRNA RHPN1-AS1 promoted cell proliferation, invasion and migration in cervical cancer via the modulation of miR-299-3p/FGF2 axis[J]. Life Sci, 2019, 239(1):116856. [15] Chen X, Qi M, Yang Q, et al. MiR-299-3p functions as a tumor suppressor in thyroid cancer by regulating SHOC2[J]. Eur Rev Med Pharmacol Sci, 2019, 23(1):232-240. [16] Li Y, Zheng D, Pan L, et al. Knockdown of TUG1 by shRNA inhibited renal cell carcinoma formation by miR-299-3p/VEGF axis in vitro and in vivo[J]. Eur J Pharmacol, 2019, 860(1):172536-172546.
2022, Vol. 29 
